Unsurprisingly, the upregulation of alternative pro-survival proteins, in particular MCL1 and BCLxL, has been observed in CLL patients with acquired resistance to venetoclax. The gene discussed is BCL2L1; the disease is B-cell chronic lymphocytic leukemia.